Key Findings from the Successful Phase 2b Clinical Trial

Mirum Pharmaceuticals (MIRM) announced that its Phase 2b VISTAS clinical trial of volixibat, targeting patients with Primary Sclerosing Cholangitis (PSC), met its primary endpoint. The study analyzed 111 patients experiencing moderate to severe pruritus, and the volixibat group showed a statistically significant improvement in the ItchRO score (reduction of 2.72 points) compared to the placebo group (reduction of 1.08 points; p<0.0001). This represents a clinically valuable outcome for patients who currently lack adequate treatment options and marks a significant milestone in the rare liver disease market, which has high unmet needs.

Differentiated Mechanism of Action of a Small Molecule IBAT Inhibitor

Volixibat is a small molecule compound that selectively inhibits the Ileal Bile Acid Transporter (IBAT), which is responsible for the reabsorption of bile acids in the intestine. Severe systemic pruritus, caused by the accumulation of bile acids in the body, can lead to significant deterioration in patients' quality of life, even inducing suicidal ideation. This drug presents an innovative approach by directly reducing bile acid levels in the blood, thereby addressing the root cause of the symptoms by blocking enterohepatic circulation.

Clinical Discontinuation Rate and Management of Safety Risks

However, the clinical trial showed that the volixibat group had a discontinuation rate of 9.1% due to adverse events, which was relatively higher than the placebo group's 2.5%. In particular, transient increases in liver function markers such as amylase, alanine aminotransferase (ALT), and bilirubin were observed, necessitating a thorough review of the safety profile. The company is conducting a detailed analysis of the safety data in collaboration with an independent expert committee, taking into account the specific characteristic that the patients' liver function is already impaired.

Regulatory Roadmap and Competitive Landscape Comparison

Mirum plans to hold a pre-NDA meeting with the U.S. Food and Drug Administration (FDA) in the summer of 2026 and submit the formal application in the second half of the year. Currently, there are no PSC treatments approved by the U.S. FDA, so approval would likely result in market exclusivity. Meanwhile, in the Primary Biliary Cholangitis (PBC) market, Lynavoy (linerixibat), developed and approved by GSK, is a strong competitor, and fierce competition for market share is expected when the indication is expanded in the future.

Investment Value and Future Growth Momentum

Immediately following the announcement of the successful volixibat clinical trial, Mirum's stock price surged by approximately 10%, reflecting strong market expectations. The company has already achieved commercial success with its other liver disease treatment, Livmarli, and is expected to maximize synergy when launching the new drug. In addition, the topline results of the Phase 2b clinical trial for the PBC indication, to be announced in the first quarter of 2027, are expected to serve as a key catalyst for further increasing the company's value.